<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31133044</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1756-9966</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>38</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>May</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of experimental &amp; clinical cancer research : CR</Title>
          <ISOAbbreviation>J Exp Clin Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis.</ArticleTitle>
        <Pagination>
          <StartPage>221</StartPage>
          <MedlinePgn>221</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">221</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13046-019-1226-8</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Extracellular signal-regulated kinases (ERKs) have been related to multiple cancers, including breast cancer, hepatocellular cancer, lung cancer and colorectal cancer. ERK1/2 inhibitor can suppress growth of KRAS-mutant pancreatic tumors by targeting cancer cell. However, no studies have shown the expression of ERK1/2 on pancreatic stromal and its effect on pancreatic cancer-stromal interaction.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Immunohistochemistry and western blotting were performed to detect the expression of p-ERK1/2 in pancreatic tissues and cells. Cell viability assay was used to study IC50 of ERK inhibitor on pancreatic cancer cells (PCCs) and primary cancer-associated pancreatic stellate cells (PSCs). Transwell migration, invasion, cell viability assay, senescence β-galactosidase staining were performed to determine the effect of ERK inhibitor on PCCs and PSCs in vitro and in vivo. The expression of key factors involved in autophagy and epithelial-to-mesenchymal transition (EMT) process were evaluated by western blotting. The expression of key factors related to cell invasiveness and malignancy were confirmed by qRT-PCR. Co-transplantation of PCC Organoid and PSC using a splenic xenograft mouse model was used to evaluated combined treatment of ERK inhibitor and autophagy inhibitor.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Immunohistochemical staining in pancreatic tumor samples and transgenetic mice detected p-ERK1/2 expression in both cancer cells and stromal cells. In pancreatic tissues, p-ERK1/2 was strongly expressed in cancer-associated PSCs compared with cancer cells and normal PSCs. PSCs were also significantly more sensitive to ERK1/2 inhibitor treatment. Inhibition of ERK1/2 suppressed EMT transition in HMPCCs, upregulated cellular senescence markers, activated autophagy in cancer-associated PSCs; and suppressed cancer-stromal interaction, which enhanced invasiveness and viability of cancer cells. We also found that chloroquine, an autophagy inhibitor, suppressed ERK inhibition-induced autophagy and promoted PSC cellular senescence, leading to significantly decreased cell proliferation. The combination of an ERK inhibitor and autophagy inhibitor suppressed liver metastasis in a splenic pancreatic cancer organoid xenograft mouse model.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data indicate that inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Zilong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohuchida</LastName>
            <ForeName>Kenoki</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-4792-1168</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan. kenoki@surg1.med.kyushu-u.ac.jp.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. kenoki@surg1.med.kyushu-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fei</LastName>
            <ForeName>Shuang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Biao</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, Shenzhen University General Hospital, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Weiyu</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Haimin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kibe</LastName>
            <ForeName>Shin</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ando</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koikawa</LastName>
            <ForeName>Kazuhiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abe</LastName>
            <ForeName>Toshiya</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iwamoto</LastName>
            <ForeName>Chika</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shindo</LastName>
            <ForeName>Koji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moriyama</LastName>
            <ForeName>Taiki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakata</LastName>
            <ForeName>Kohei</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyasaka</LastName>
            <ForeName>Yoshihiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohtsuka</LastName>
            <ForeName>Takao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mizumoto</LastName>
            <ForeName>Kazuhiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Center of Kyushu University Hospital, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hashizume</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Masafumi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan. mnaka@surg1.med.kyushu-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Exp Clin Cancer Res</MedlineTA>
        <NlmUniqueID>8308647</NlmUniqueID>
        <ISSNLinking>0392-9078</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007191">Indazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C587178">SCH772984</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>886U3H6UFF</RegistryNumber>
          <NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="C535150">MAPK1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="C000629649">MAPK3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021441" MajorTopicYN="N">Carcinoma, Pancreatic Ductal</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007191" MajorTopicYN="N">Indazoles</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048052" MajorTopicYN="N">Mitogen-Activated Protein Kinase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058954" MajorTopicYN="N">Pancreatic Stellate Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017154" MajorTopicYN="N">Stromal Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer–stromal interaction</Keyword>
        <Keyword MajorTopicYN="N">Cellular senescence</Keyword>
        <Keyword MajorTopicYN="N">ERK1/2</Keyword>
        <Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>
        <Keyword MajorTopicYN="N">Pancreatic stellate cell</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31133044</ArticleId>
        <ArticleId IdType="pmc">PMC6537367</ArticleId>
        <ArticleId IdType="doi">10.1186/s13046-019-1226-8</ArticleId>
        <ArticleId IdType="pii">10.1186/s13046-019-1226-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Stewart BW, Wild CP. World cancer report 2014. World Heal Organ [Internet] 2014;1–2. Available from: https://www.who.int/cancer/publications/WRC_2014/en/.</Citation>
        </Reference>
        <Reference>
          <Citation>Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al.  Metastatic patterns in adenocarcinoma. Cancer. 2006;106:1624–1633. doi: 10.1002/cncr.21778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.21778</ArticleId>
            <ArticleId IdType="pubmed">16518827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975–2013. Natl Cancer Institute Bethesda, MD [Internet]. 2016. Available from: http://seer.cancer.gov/csr/1975_2013/.</Citation>
        </Reference>
        <Reference>
          <Citation>Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al.  Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110:2484–2492. doi: 10.1002/cncr.23074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.23074</ArticleId>
            <ArticleId IdType="pubmed">17941009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20966025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16862189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut. 1998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1727174</ArticleId>
            <ArticleId IdType="pubmed">9771417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte MV, Haber PS, Darby SJ, Rodgers SC, McCaughan GW, Korsten MA, et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1727467</ArticleId>
            <ArticleId IdType="pubmed">10075961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whatcott CJ, Diep CH, Jiang P, Watanabe A, Lobello J, Sima C, et al.  Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015;21:3561–3568. doi: 10.1158/1078-0432.CCR-14-1051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1051</ArticleId>
            <ArticleId IdType="pmc">PMC4526394</ArticleId>
            <ArticleId IdType="pubmed">25695692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta - Mol Cell Res. 2007;1773:1263–1284. doi: 10.1016/j.bbamcr.2006.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2006.10.001</ArticleId>
            <ArticleId IdType="pmc">PMC2696318</ArticleId>
            <ArticleId IdType="pubmed">17126425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, et al. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist. 2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3380875</ArticleId>
            <ArticleId IdType="pubmed">22584435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Virtakoivu R, Mai A, Mattila E, De Franceschi N, Imanishi SY, Corthals G, et al. Vimentin-ERK signaling uncouples slug gene regulatory function. Cancer Res. 2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25855378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng KY, Chan LH, Chai S, Tong M, Guan XY, Lee NP, et al. TP53INP1 downregulation activates a p73-dependent DUSP10/ERK signaling pathway to promote metastasis of hepatocellular carcinoma. Cancer Res. 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28674078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, Luk F, Yang JL, Walsh WR. Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model. Anticancer Res. 2011;31:1147–1152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21508358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ai X, Wu Y, Zhang W, Zhang Z, Jin G, Zhao J, et al.  Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer. Cancer Biol Ther. 2013;14:1059–1067. doi: 10.4161/cbt.26427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cbt.26427</ArticleId>
            <ArticleId IdType="pmc">PMC3925661</ArticleId>
            <ArticleId IdType="pubmed">24025354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Principe D R, Diaz A M, Torres C, Mangan R J, DeCant B, McKinney R, Tsao M-S, Lowy A, Munshi H G, Jung B, Grippo P J. TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function. Oncogene. 2017;36(30):4336–4348. doi: 10.1038/onc.2016.500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2016.500</ArticleId>
            <ArticleId IdType="pmc">PMC5537609</ArticleId>
            <ArticleId IdType="pubmed">28368414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes Tikvah K., Neel Nicole F., Hu Chaoxin, Gautam Prson, Chenard Melissa, Long Brian, Aziz Meraj, Kassner Michelle, Bryant Kirsten L., Pierobon Mariaelena, Marayati Raoud, Kher Swapnil, George Samuel D., Xu Mai, Wang-Gillam Andrea, Samatar Ahmed A., Maitra Anirban, Wennerberg Krister, Petricoin Emanuel F., Yin Hongwei H., Nelkin Barry, Cox Adrienne D., Yeh Jen Jen, Der Channing J. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell. 2016;29(1):75–89. doi: 10.1016/j.ccell.2015.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.11.011</ArticleId>
            <ArticleId IdType="pmc">PMC4816652</ArticleId>
            <ArticleId IdType="pubmed">26725216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15894267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachem MG, Schünemann M, Ramadani M, Siech M, Beger H, Buck A, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15825074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachem MG, Schneider E, Groß H, Weidenbach H, Schmid RM, Menke A, et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 1998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9679048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koikawa K, Ohuchida K, Ando Y, Kibe S, Nakayama H, Takesue S, et al. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Cancer Lett. 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29580808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikenaga Naoki, Ohuchida Kenoki, Mizumoto Kazuhiro, Cui Lin, Kayashima Tadashi, Morimatsu Katsuya, Moriyama Taiki, Nakata Kohei, Fujita Hayato, Tanaka Masao. CD10+ Pancreatic Stellate Cells Enhance the Progression of Pancreatic Cancer. Gastroenterology. 2010;139(3):1041-1051.e8. doi: 10.1053/j.gastro.2010.05.084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2010.05.084</ArticleId>
            <ArticleId IdType="pubmed">20685603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endo S, Nakata K, Ohuchida K, Takesue S, Nakayama H, Abe T, et al. Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mice. Gastroenterology. Elsevier, Inc; 2017;152:1492–1506.e24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28126348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, et al.  Radiation to stromal fibroblasts increases invasiveness of pancreatic Cancer cells through tumor-stromal interactions. Cancer Res. 2004;64:3215–3222. doi: 10.1158/0008-5472.CAN-03-2464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-03-2464</ArticleId>
            <ArticleId IdType="pubmed">15126362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boj SF, IL HC, Baker LA, Chio IIC, Engle DD, Corbo V, et al.  Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160:324–338. doi: 10.1016/j.cell.2014.12.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.12.021</ArticleId>
            <ArticleId IdType="pmc">PMC4334572</ArticleId>
            <ArticleId IdType="pubmed">25557080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chijiiwa Y, Moriyama T, Ohuchida K, Nabae T, Ohtsuka T, Miyasaka Y, et al.  Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by targeting PODXL. Int J Oncol. 2016;48:1688–1700. doi: 10.3892/ijo.2016.3389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2016.3389</ArticleId>
            <ArticleId IdType="pubmed">26892887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng B, Ohuchida K, Chijiiwa Y, Zhao M, Mizuuchi Y, Cui L, et al.  CD146 attenuation in cancer-associated fibroblasts promotes pancreatic cancer progression. Mol Carcinog. 2016;55:1560–1572. doi: 10.1002/mc.22409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.22409</ArticleId>
            <ArticleId IdType="pubmed">26373617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4160307</ArticleId>
            <ArticleId IdType="pubmed">23550210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3956037</ArticleId>
            <ArticleId IdType="pubmed">22588877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahadevan D., Von Hoff D. D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Molecular Cancer Therapeutics. 2007;6(4):1186–1197. doi: 10.1158/1535-7163.MCT-06-0686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-06-0686</ArticleId>
            <ArticleId IdType="pubmed">17406031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kikuta Kazuhiro, Masamune Atsushi, Watanabe Takashi, Ariga Hiroyuki, Itoh Hiromichi, Hamada Shin, Satoh Kennichi, Egawa Shinichi, Unno Michiaki, Shimosegawa Tooru. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochemical and Biophysical Research Communications. 2010;403(3-4):380–384. doi: 10.1016/j.bbrc.2010.11.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2010.11.040</ArticleId>
            <ArticleId IdType="pubmed">21081113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013;3:742–750. doi: 10.1158/2159-8290.CD-13-0070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-0070</ArticleId>
            <ArticleId IdType="pubmed">23614898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, et al. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17879119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikenaga N, Ohuchida K, Mizumoto K, Cui L, Kayashima T, Morimatsu K, et al.  CD10+pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology. 2010;139:1041–1051. doi: 10.1053/j.gastro.2010.05.084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2010.05.084</ArticleId>
            <ArticleId IdType="pubmed">20685603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppé J, Rodier F, Patil CK, Freund A, Desprez P, Campisi J. Tumor suppressor and aging biomarker p16 INK4a induces cellular senescence without the associated inflammatory secretory phenotype * □. 2011;286:36396–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3196093</ArticleId>
            <ArticleId IdType="pubmed">21880712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vijayaraghavan Smruthi, Karakas Cansu, Doostan Iman, Chen Xian, Bui Tuyen, Yi Min, Raghavendra Akshara S., Zhao Yang, Bashour Sami I., Ibrahim Nuhad K., Karuturi Meghan, Wang Jing, Winkler Jeffrey D., Amaravadi Ravi K., Hunt Kelly K., Tripathy Debu, Keyomarsi Khandan. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nature Communications. 2017;8:15916. doi: 10.1038/ncomms15916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms15916</ArticleId>
            <ArticleId IdType="pmc">PMC5490269</ArticleId>
            <ArticleId IdType="pubmed">28653662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Notta F, Navab R, Joseph J, Ibrahimov E, Xu J, et al. Senescent carcinoma-associated fibroblasts upregulate IL8 to enhance Prometastatic phenotypes. Mol Cancer Res. 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27678171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broutier L, Mastrogiovanni G, Verstegen MMA, Francies HE, Gavarró LM, Bradshaw CR, et al.  Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23:1424–1435. doi: 10.1038/nm.4438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4438</ArticleId>
            <ArticleId IdType="pmc">PMC5722201</ArticleId>
            <ArticleId IdType="pubmed">29131160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L, Holtzinger A, Jagan I, Begora M, Lohse I, Ngai N, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med. 2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4753163</ArticleId>
            <ArticleId IdType="pubmed">26501191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16788754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan Zilong, Ohuchida Kenoki, Zheng Biao, Okumura Takashi, Takesue Shin, Nakayama Hiromichi, Iwamoto Chika, Shindo Koji, Moriyama Taiki, Nakata Kohei, Miyasaka Yoshihiro, Ohtsuka Takao, Mizumoto Kazuhiro, Oda Yoshinao, Hashizume Makoto, Nakamura Masafumi. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Journal of Cancer Research and Clinical Oncology. 2019;145(5):1147–1164. doi: 10.1007/s00432-019-02860-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-019-02860-z</ArticleId>
            <ArticleId IdType="pubmed">30770989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandol S, Edderkaoui M, Gukovsky I, Lugea A, Gukovskaya A. Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4573641</ArticleId>
            <ArticleId IdType="pubmed">19896098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozono S, Ohuchida K, Eguchi D, Ikenaga N, Fujiwara K, Cui L, et al.  Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 2013;73:2345–2356. doi: 10.1158/0008-5472.CAN-12-3180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-3180</ArticleId>
            <ArticleId IdType="pubmed">23348422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida M, Miyasaka Y, Ohuchida K, Okumura T, Zheng B, Torata N, et al. Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer – stromal interactions in a mouse xenograft model. 2016;107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5084662</ArticleId>
            <ArticleId IdType="pubmed">27487486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Lopez N, Athonvarangkul D, Mishall P, Sahu S, Singh R. Autophagy proteins regulate ERK phosphorylation. Nat Commun [Internet]. Nat Publ Group; 2013;4:2799. Available from: http://www.nature.com/ncomms/2013/131118/ncomms3799/full/ncomms3799.html#f4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3868163</ArticleId>
            <ArticleId IdType="pubmed">24240988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, et al. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res. 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2676677</ArticleId>
            <ArticleId IdType="pubmed">19010903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García-Prat L, Martínez-Vicente M, Perdiguero E, Ortet L, Rodríguez-Ubreva J, Rebollo E, et al. Autophagy maintains stemness by preventing senescence. Nature. 2016;</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26738589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer [Internet]. Nat Publ Group; 2010;10:51–7. Available from: 10.1038/nrc2772%5Cnhttp://www.nature.com/nrc/journal/v10/n1/pdf/nrc2772.pdf</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3672965</ArticleId>
            <ArticleId IdType="pubmed">20029423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirzayans R, Andrais B, Hansen G, Murray D. Role of p16 INK4A in replicative senescence and DNA damage-induced premature senescence in p53-deficient human cells. Biochem Res Int. 2012;2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3424640</ArticleId>
            <ArticleId IdType="pubmed">22924132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer. 2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3288293</ArticleId>
            <ArticleId IdType="pubmed">22025288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capparelli C, Guido C, Whitaker-Menezes D, Bonuccelli G, Balliet R, Pestell TG, et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis, via glycolysis and ketone production. Cell Cycle. 2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3383590</ArticleId>
            <ArticleId IdType="pubmed">22684298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White E. Autophagy and p53. Cold Spring Harb Perspect Med. 2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4817743</ArticleId>
            <ArticleId IdType="pubmed">27037419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang HT, Lee KB, Kim SY, Choi HR, Park SC. Autophagy impairment induces premature senescence in primary human fibroblasts. PLoS One. 2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3152578</ArticleId>
            <ArticleId IdType="pubmed">21858089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder Cancer. Cell. 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5890941</ArticleId>
            <ArticleId IdType="pubmed">29625057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del CA, Conciatori F, Incani UC, Bazzichetto C, Falcone I, Corbo V, et al. Therapeutic potential of combined BRAF / MEK blockade in BRAF -wild type preclinical tumor models. J Exp Clin Cancer Res. 2018:1–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6038340</ArticleId>
            <ArticleId IdType="pubmed">29986755</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
